← Leaderboards
Bruce S Bochner
Johns Hopkins University
$17,391,451
Attributed
$18,028,720
Total exposure
15
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$29,192,139 · 17
By mechanism
U19$11,951,763 · 5
R01$8,494,013 · 4
P01$5,810,149 · 3
T32$2,021,852 · 2
R21$509,362 · 2
R56$405,000 · 1
Top collaborators
- Robert P Schleimer3 shared
- Evan Alexander Scott2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Ronald L Schnaar$20,308,382
Others in their field
Top investigators on “Eosinophil”
- Marc E. Rothenberg · Cincinnati Childrens Hosp Med Ctr$44,428,890
- Joshua A Boyce · Brigham And Women'S Hospital$23,179,588
- Hirohito Kita · Mayo Clinic Arizona$21,211,797
- Nizar N Jarjour · University Of Wisconsin Madison$19,170,779
- David H Broide · University Of California, San Diego$17,873,137
- Peter F Weller · Boston University Medical Campus$17,472,817
Research focus
EosinophilMast CellLigandsTissuesCellsIn VitroSialic Acid Binding Ig-Like LectinAllergicIn VivoLungLectinSialic AcidsAsthmaBasophilsCollaborationsAntibodiesBaseInflammatoryImmunoglobulinsInflammatory ResponsePolysaccharidesResponseAllergic DiseaseMouse Model
Grant awards (76)
Using siglecs and their ligands to treat allergic diseases SALTAD$1,505,741
U19 · FY2022 · AI · contact PI
Defining Siglec-6 and Siglec-8 function on effector cells of allergic diseases$387,558
U19 · FY2022 · AI · contact PI
Northwestern University Allergy and Immunology Research (NUAIR) Program$248,532
T32 · FY2022 · AI
Exploiting Siglec-6 for targeted anti-allergy drug delivery into human mast cells$230,719
R21 · FY2022 · AI · contact PI
Human mast cell and tissue acquisition core$122,899
U19 · FY2022 · AI · contact PI
Core A Admin$25,386
U19 · FY2022 · AI · contact PI
Using siglecs and their ligands to treat allergic diseases SALTAD$1,516,002
U19 · FY2021 · AI · contact PI
Defining Siglec-6 and Siglec-8 function on effector cells of allergic diseases$422,909
U19 · FY2021 · AI · contact PI
Northwestern University Allergy and Immunology Research (NUAIR) Program$311,515
T32 · FY2021 · AI
Exploiting Siglec-6 for targeted anti-allergy drug delivery into human mast cells$186,674
R21 · FY2021 · AI · contact PI
Human mast cell and tissue acquisition core$134,376
U19 · FY2021 · AI · contact PI
Core A Admin$27,742
U19 · FY2021 · AI · contact PI
Using siglecs and their ligands to treat allergic diseases SALTAD$1,504,730
U19 · FY2020 · AI · contact PI
Defining Siglec-6 and Siglec-8 function on effector cells of allergic diseases$389,372
U19 · FY2020 · AI · contact PI
Northwestern University Allergy and Immunology Research (NUAIR) Program$297,098
T32 · FY2020 · AI
Human mast cell and tissue acquisition core$156,085
U19 · FY2020 · AI · contact PI
Core A Admin$37,247
U19 · FY2020 · AI · contact PI
Using siglecs and their ligands to treat allergic diseases SALTAD$1,517,513
U19 · FY2019 · AI · contact PI
Defining Siglec-6 and Siglec-8 function on effector cells of allergic diseases$456,439
U19 · FY2019 · AI · contact PI
Human mast cell and tissue acquisition core$192,312
U19 · FY2019 · AI · contact PI
Core A Admin$35,998
U19 · FY2019 · AI · contact PI
Using siglecs and their ligands to treat allergic diseases SALTAD$1,556,002
U19 · FY2018 · AI · contact PI
Defining Siglec-6 and Siglec-8 function on effector cells of allergic diseases$395,000
U19 · FY2018 · AI · contact PI
Regulation of food allergy and anaphylaxis by IL 33$386,250
R01 · FY2018 · AI · contact PI
Human mast cell and tissue acquisition core$158,000
U19 · FY2018 · AI · contact PI
Core A Admin$39,500
U19 · FY2018 · AI · contact PI
Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders$386,250
R01 · FY2017 · AI · contact PI
Regulation of food allergy and anaphylaxis by IL 33$386,250
R01 · FY2017 · AI · contact PI
Treating lung inflammation by targeting Siglecs$311,051
P01 · FY2017 · HL · contact PI
Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders$386,250
R01 · FY2016 · AI · contact PI
Treating lung inflammation by targeting Siglecs$321,603
P01 · FY2016 · HL · contact PI
Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders$386,250
R01 · FY2015 · AI · contact PI
Treating lung inflammation by targeting Siglecs$317,822
P01 · FY2015 · HL · contact PI
Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders$386,250
R01 · FY2014 · AI · contact PI
Treating lung inflammation by targeting Siglecs$318,088
P01 · FY2014 · HL · contact PI
Treating lung inflammation by targeting Siglecs$308,027
P01 · FY2013 · HL · contact PI
Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders$116,016
R01 · FY2013 · AI · contact PI
Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders$36,979
R01 · FY2013 · AI · contact PI
Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders$405,000
R56 · FY2012 · AI · contact PI
Treating lung inflammation by targeting Siglecs$331,325
P01 · FY2012 · HL · contact PI
Basic and Clinical Immunology$253,881
T32 · FY2012 · AI · contact PI
Targeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro and In Vivo$394,207
R01 · FY2011 · AI · contact PI
Treating lung inflammation by targeting Siglecs$338,802
P01 · FY2011 · HL · contact PI
Basic and Clinical Immunology$201,458
T32 · FY2011 · AI · contact PI
Targeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro and In Vivo$398,189
R01 · FY2010 · AI · contact PI
Determination of Cellular and Clinical Thresholds for IgE-Mediated Reactivity$298,875
U19 · FY2010 · AI · contact PI
Targeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro and In Vivo$232,945
R01 · FY2010 · AI · contact PI
Basic and Clinical Immunology$227,386
T32 · FY2010 · AI · contact PI
Targeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro and In Vivo$402,210
R01 · FY2009 · AI · contact PI
Determination of Cellular and Clinical Thresholds for IgE-Mediated Reactivity$293,220
U19 · FY2009 · AI · contact PI
Basic and Clinical Immunology$235,647
T32 · FY2009 · AI · contact PI
Targeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro and In Vivo$402,210
R01 · FY2008 · AI · contact PI
Determination of Cellular and Clinical Thresholds for IgE-Mediated Reactivity$284,799
U19 · FY2008 · AI · contact PI
Basic and Clinical Immunology$246,335
T32 · FY2008 · AI · contact PI
Targeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro and In Vivo$409,896
R01 · FY2007 · AI · contact PI
Adhesion Molecule Biology in Allergic Cells$348,813
R01 · FY2007 · AI · contact PI
Determination of Cellular and Clinical Thresholds for IgE-Mediated Reactivity$255,046
U19 · FY2007 · AI · contact PI
Adhesion Molecule Biology in Allergic Cells$359,231
R01 · FY2006 · AI · contact PI
Cellular and Clinical Thresholds for IgE-Mediated Reacti$239,012
U19 · FY2006 · AI · contact PI
Adhesion Molecule Biology in Allergic Cells$367,875
R01 · FY2005 · AI
Tissue-Specific Mechanisms of Allergic Inflammation$984,172
P01 · FY2004 · AI
Adhesion Molecule Biology in Allergic Cells$367,875
R01 · FY2004 · AI
Tissue-Specific Mechanisms of Allergic Inflammation$960,450
P01 · FY2003 · AI
GLYCOLIPID E-SELECTIN LIGANDS ON HUMAN GRANULOCYTES$341,200
R01 · FY2003 · AI
Adhesion Molecule Biology in Allergic Cells$183,938
R01 · FY2003 · AI
Adhesion Molecule Biology in Allergic Cells$91,969
R21 · FY2003 · AI
Tissue-Specific Mechanisms of Allergic Inflammation$817,050
P01 · FY2002 · AI
GLYCOLIPID E-SELECTIN LIGANDS ON HUMAN GRANULOCYTES$333,721
R01 · FY2002 · AI
INTEGRINS AND CHEMOKINES IN ALLERGIC CELL RECRUITMENT$286,244
R01 · FY2002 · AI
Role of TNF alpha in allergic late phase response$0
P01 · FY2002 · AI
Tissue-Specific Mechanisms of Allergic Inflammation$801,759
P01 · FY2001 · AI
GLYCOLIPID E-SELECTIN LIGANDS ON HUMAN GRANULOCYTES$326,869
R01 · FY2001 · AI
INTEGRINS AND CHEMOKINES IN ALLERGIC CELL RECRUITMENT$277,909
R01 · FY2001 · AI
Role of TNF alpha in allergic late phase response$0
P01 · FY2001 · AI
GLYCOLIPID E-SELECTIN LIGANDS ON HUMAN GRANULOCYTES$320,372
R01 · FY2000 · AI
INTEGRINS AND CHEMOKINES IN ALLERGIC CELL RECRUITMENT$269,814
R01 · FY2000 · AI